Intramuscular desferrioxamine in patients with Alzheimer's disease
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Although epidemiological and biochemical evidence suggests that aluminium may be associated with Alzheimer's disease (AD), there is no convincing proof of a causal link for aluminium in disease progression. We have completed a two year, single-blind study to investigate whether the progression of dementia could be slowed by the trivalent ion chelator, desferrioxamine. 48 patients with probable AD were randomly assigned to receive desferrioxamine (125 mg intramuscularly twice daily, 5 days per week, for 24 months), oral placebo (lecithin), or no treatment. No significant differences in baseline measures of intelligence, memory, or speech ability existed between groups. Activities of daily living were assessed and videorecorded at 6, 12, 18, and 24 month intervals. There were no differences in the rate of deterioration of patients receiving either placebo or no treatment. Desferrioxamine treatment led to significant reduction in the rate of decline of daily living skills as assessed by both group means (p = 0.03) and variances (p less than 0.04). The mean rate of decline was twice as rapid for the no-treatment group. Appetite (n = 4) and weight (n = 1) loss were the only reported side-effects. We conclude that sustained administration of desferrioxamine may slow the clinical progression of the dementia associated with AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, iron chelators have been shown to ameliorate the development of fibril formation/neurodegeneration/dementia/AD (Amit et al. 2008; Avramovich-Tirosh et al. 2007a; Bandyopadhyay et al. 2006; Barnham et al. 2004; Biran et al. 2009; Bolognin et al. 2009a; Crapper McLachlan et al. 1991; Cuajungco et al. 2000; Faux et al. 2010; Finefrock et al. 2003; Liu et al. 2009b, c, 2010; Mancino et al”
From Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples (2010) · cites this paper as Crapper McLachlan et al. 1991
In the citing paper
“The benefits of administration of desferrioxamine in Alzheimer’s, for instance, have been known for nearly 20 years (Crapper McLachlan et al. 1991), benefits since observed with other iron chelators”
From Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples (2010) · cites this paper as Crapper McLachlan et al. 1991
In the citing paper
“Crapper McLachlan and colleagues217 showed a substantial reduction in the rate of deterioration of daily living skills in 48 patients with Alzheimer’s disease who were given deferrioxamine (125 mg intramuscular two times a day, five times per week for 24 months) when compared with patients with Alzheimer’s disease given placebo.”
From The role of iron in brain ageing and neurodegenerative disorders (2014) · cites this paper as [217]
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Manual for the Wechsler Adult Intelligence Scale.
Wechsler, D. (1955) · Psychological Corp. eBooks · Cited by 4,941
. Cerebral blood flow in dementia.
Hachinski, V. C., Iliff, L. D., Zilhka, E., Du Boulay, G. H., McAllister, V. L., Marshall, J., Russell, R. W. R., & Symon, L. (1975) · Archives of Neurology · doi:10.1001/archneur.1975.00490510088009 · Cited by 3,186
Behavior modification in applied settings
Kazdin, A. E. (1975) · Cited by 1,086
Geographical relation between Alzheimer's disease and aluminum in drinking water.
Martyn, C. N., Barker, D. J. P., Osmond, C., Harris, E. C., Edwardson, J. A., & Lacey, R. F. (1989) · PubMed · Cited by 587
Visual and Auditory Neurotoxicity in Patients Receiving Subcutaneous Deferoxamine Infusions
Olivieri, N. F., Buncic, J. R., Chew, E., Gallant, T., Harrison, R. V., Keenan, N., Logan, W., Mitchell, D., Ricci, G., Skarf, B., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198604033141402 · Cited by 429
Continuous Subcutaneous Administration of Deferoxamine in Patients with Iron Overload
Propper, R. D., Cooper, B., Rufo, R. R., Nienhuis, A. W., Anderson, W. F., Bunn, H. F., Rosenthal, A., & Nathan, D. G. (1977) · New England Journal of Medicine · doi:10.1056/nejm197708252970804 · Cited by 258
Crapper, D. R., Quittkat, S., Krishnan, S. S., Dalton, A. J., & De Boni, U. (1980) · Acta Neuropathologica · doi:10.1007/bf00688530 · Cited by 232
Effect of a specific iron chelating agent on animal models of inflammation.
Blake, D. R., Hall, N. D., BACON, P. A., Dieppe, P. A., Halliwell, B. B., & Gutteridge, J. M. C. (1983) · Annals of the Rheumatic Diseases · doi:10.1136/ard.42.1.89 · Cited by 125
Iron in the synovial membrane in rheumatoid arthritis and other joint diseases.
Muirden, K. D., & Senator, G. B. (1968) · Annals of the Rheumatic Diseases · doi:10.1136/ard.27.1.38 · Cited by 113
Cited by
Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease
Stockwell, B. R., Friedmann Angeli, J. P., Bayir, H., Bush, A. I., Conrad, M., Dixon, S. J., Fulda, S., Gascón, S., Hatzios, S. K., Kagan, V. E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.021 · Cited by 7,695
“…AD models, iron chelators rescue cognitive deficits; a phase 2 clinical trial reported that desferrioxamine delayed deterioration in AD (Crapper McLachlan et al., 1991) ACSL4 inhibitors decrease FTD in humans Long-term use of pioglitazone, a recently discovered ACSL4 inhibitor, decreases…”
Neurodegenerative diseases and oxidative stress
Barnham, K. J., Masters, C. L., & Bush, A. I. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1330 · Cited by 3,683
Oxidative stress hypothesis in Alzheimer’s disease
Markesbery, W. R. (1997) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(96)00629-6 · Cited by 2,383
The role of iron in brain ageing and neurodegenerative disorders
Ward, R. J., Zucca, F. A., Duyn, J. H., Crichton, R. R., & Zecca, L. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70117-6 · Cited by 1,819
Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells.
Schreck, R., Meier, B., Männel, D. N., Dröge, W., & Baeuerle, P. A. (1992) · The Journal of experimental medicine · doi:10.1084/jem.175.5.1181 · Cited by 1,508
“sion of the dementia associated with Alzheimer's disease (39).”
Metadata
- Authors
- MCLACHLAN, D.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 1991-06
- Volume
- 337
- Issue
- 8753
- Pages
- 1304-1308
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2054113864
- Cited by
- 764
- References
- 19
- Citations by year
- 2026: 18 · 2025: 31 · 2024: 30 · 2023: 34 · 2022: 25 · 2021: 28 · 2020: 32 · 2019: 26 · 2018: 23 · 2017: 19 · 2016: 26 · 2015: 23 · 2014: 27 · 2013: 15 · 2012: 22
- FWCI
- 18.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Aluminum toxicity and tolerance in plants and animals
- Keywords
- deferoxamine, Alzheimer's disease, aluminum, dementia progression, activities of daily living, intramuscular administration, adverse effects
- MeSH terms
- Aged, Alzheimer Disease, Analysis of Variance, Chromatography, High Pressure Liquid, Deferoxamine, Female, Humans, Injections, Intramuscular, Male, Middle Aged, Prospective Studies, Psychological Tests, Single-Blind Method
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intramuscular desferrioxamine in patients with Alzheimer's disease. https://app.cochat.ai/papers/10.1016/0140-6736(91)92978-b
- The paper
- MCLACHLAN, D. (1991). Intramuscular desferrioxamine in patients with Alzheimer's disease. The Lancet. https://doi.org/10.1016/0140-6736(91)92978-b
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.